Fig. 5 | Signal Transduction and Targeted Therapy

Fig. 5

From: A first-in-class selective inhibitor of ERK1/2 and ERK5 overcomes drug resistance with a single-molecule strategy

Fig. 5

SKLB-D18 induced complete autophagy in MDA-MB-231 and MDA-MB-468 cells. a Immunofluorescence analysis of LC3 levels following treatment with SKLB-D18 (5 μM) in MDA-MB-231 and MDA-MB-468 cells for 24 h. b Immunoblotting analysis of protein levels of p62, LC3I/II in MDA-MB-231 and MDA-MB-468 cells following treatment with SKLB-D18 (1, 2.5, 5 μM) for 24 h. c Immunoblotting analysis of protein levels of p-mTOR, mTOR, p-p70S6K, p70S6K following treatment with SKLB-D18 (5 μM) and combination of BVD-523 (5 μM) and XMD8-92 (5 μM) for 24 h. d Immunofluorescence analysis in cells following co-incubation of SKLB-D18 (5 µM) and BafA1 (10 nM) after transfecting with GFP-mRFP-LC3 adenovirus. e Immunofluorescence analysis of co-localization of LC3 and LAMP1 in cells following co-incubation of SKLB-D18 (5 µM) and CQ (1 μM). Scale bar, 100 μm. Data are presented as Mean ± SD. Compared to the Control group: ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001. Compared to the SKLB-D18 treatment group: ##p < 0.01

Back to article page